REVIEW
|
doi:10.20944/preprints201810.0577.v1
Subject:
Medicine And Pharmacology,
Oncology And Oncogenics
Keywords:
myeloma; daratumumab; elotuzumab; isatuximab; CD38; JNJ- 63723283; denosumab; checkpoint inhibitors; BCMA; bispecific T-cell engager; antibody-drug conjugates
Online: 24 October 2018 (12:11:23 CEST)
REVIEW
|
doi:10.20944/preprints202401.1861.v1
Subject:
Biology And Life Sciences,
Life Sciences
Keywords:
Bispecific; immunotherapy; cancer; cytokine; antibodies
Online: 25 January 2024 (15:51:41 CET)
ARTICLE
|
doi:10.20944/preprints202210.0028.v1
Subject:
Biology And Life Sciences,
Immunology And Microbiology
Keywords:
EGFR; HER2; bispecific antibody; ADCC; CDC; canine osteosarcoma
Online: 5 October 2022 (09:45:16 CEST)
ARTICLE
|
doi:10.20944/preprints202311.0769.v1
Subject:
Chemistry And Materials Science,
Medicinal Chemistry
Keywords:
Bispecific radiotracers; PSMA; FAP; PET/CT; Gallium-68; prostate cancer
Online: 13 November 2023 (08:55:55 CET)
REVIEW
|
doi:10.20944/preprints202311.0307.v1
Subject:
Biology And Life Sciences,
Biology And Biotechnology
Keywords:
monoclonal antibodies; variants resistance; bispecific antibodies; engineered antibodies; antiviral therapy
Online: 6 November 2023 (10:38:14 CET)
REVIEW
|
doi:10.20944/preprints202309.1180.v1
Subject:
Medicine And Pharmacology,
Hematology
Keywords:
myeloma; daratumumab; bispecific antibodies; chimeric antigen receptor T-cells; immunotherapy
Online: 19 September 2023 (05:28:58 CEST)
REVIEW
|
doi:10.20944/preprints202309.1136.v1
Subject:
Biology And Life Sciences,
Immunology And Microbiology
Keywords:
Immunotherapy; autoimmune diseases; monoclonal antibodies; bispecific antibodies; CAR-T cells
Online: 18 September 2023 (07:17:18 CEST)
REVIEW
|
doi:10.20944/preprints202109.0212.v1
Subject:
Biology And Life Sciences,
Cell And Developmental Biology
Keywords:
BCMA; CAR T cell; Multiple Myeloma; Refractory/Relapsed; ADCs; Bispecific Antibody
Online: 13 September 2021 (12:36:12 CEST)
REVIEW
|
doi:10.20944/preprints202207.0256.v1
Subject:
Medicine And Pharmacology,
Oncology And Oncogenics
Keywords:
cancer; immunotherapy; adverse events; immune checkpoints inhibitors; chimeric antigen receptor therapy; bispecific antibodies; toxicity; renal; oncology
Online: 18 July 2022 (09:21:56 CEST)
REVIEW
|
doi:10.20944/preprints202007.0016.v1
Subject:
Medicine And Pharmacology,
Pharmacology And Toxicology
Keywords:
myeloma; BCMA; bispecific T-cell engager; antibody-drug conjugates; chimeric antigen receptor T-cells; belantamab mafodotin; idecabtagene vicleucel; JNJ-68284528
Online: 3 July 2020 (07:30:57 CEST)